Skip to main content
. Author manuscript; available in PMC: 2016 Sep 1.
Published in final edited form as: CNS Drugs. 2015 Sep;29(9):759–771. doi: 10.1007/s40263-015-0277-4

Table 2.

Adverse effect or risk mitigation strategies for the disease modifying therapies

Disease Modifying Agent Adverse effect or risk Mitigation
Interferon-beta
  • Flu-like symptoms

  • Injection site reactions

  • Depression

  • NSAIDs or acetaminophen, hydration.

  • Applying ice to the site prior to injection, site rotation, and proper injection techniques.

    Screen and monitor for depression, suicidal ideation

Glatiramer acetate
  • Injection site reactions

  • Immediate post-injection systemic reaction

  • Applying ice to the site prior to injection, site rotation, and proper injection techniques

Mitoxantrone
  • Congestive heart failure,

  • Secondary AML,

  • Amenorrhea

  • Limit dosing to a cumulative 140 mg/m2 (approximatei 10 courses).

  • Monitor blood counts after 60 mg/m2

Natalizumab
  • PML Hypersensitivity reactions

  • Infusion reactions

  • Stratify PML risk by JCV Ab status, prior immune suppression, and duration of therapy

  • Pretreat with loratadine and acetaminophen

  • Routine anti-natalizumab antibody testing and MRI brain especially if neurologic symptoms arise or worsen

Fingolimod
  • First-dose cardiac events (bradycardia, AV block, cardiac arrest, arrhythmias)

  • Herpes infection

  • Macular edema

  • PML

  • Headaches

  • First-dose observation for 6 hours with hourly heart rate and blood pressure measurements.

  • Vaccination with varicella vaccine if VZV IgG negative.

  • Acyclovir for herpetic infections.

  • Eye exams or OCT for edema. Patients to monitor for metamorphopsia.

  • No current guidelines for PML. Patients however should be aware of PML symptoms

Teriflunomide
  • Teratogenesis

  • Liver toxicity

  • Reactivation of latent tuberculosis

  • Ensure proper contraception for both male and female patients

  • Contraindication for existing liver disease or TB exposure.

  • Accelerated elimination via cholestyramine (8 g three times daily for 11 days) or activated charcoal (50 g twice daily for 11 days)

Dimethyl fumarate
  • Flushing

  • GI: Abdominal pain, diarrhea, nausea

  • PML

  • Aspirin 325 mg 30 minutes prior.

  • Intake with full stomach, may also consider food with fat content peanut butter, chocolate milk, olive oil, almonds, cashews, potato chips, or avocados.

  • Monitor lymphocyte counts routinely, check JVC Ab if <500

Alemtuzumab
  • Infusion reactions

  • Infections

  • Autoantibody disorders (thyroid, ITP, anti-GBM disease)

  • Cancers (thyroid, melanoma)

  • Pretreatment with methylprednisolone 1000 mg antipyretics, and antihistamines

  • Clinical monitoring for UTI, URI

  • Acyclovir prophylaxis for herpetic infection

Ab = antibodies; AML = acute myelogenous leukemia; AV = atrioventricular; GBM = glomerular basement membrane; GI = gastrointestinal; ITP = idiopathic thrombocytopenic purpura; JCV = John Cunningham virus; NSAIDs = nonsteroidal anti-inflammatory drugs; OCT = optical coherence tomography; TB = tuberculosis; URI = upper respiratory tract infections; UTI = urinary tract infections; VZV = varicella zoster virus.